Computing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical Characteristics

Human Leukocyte Antigen (HLA) is an essential component of the immune system which stimulates immune cells to provide protection and defense against cancer. More than thousands of HLA alleles have been reported in the literature; but, only a specific set of HLA alleles expressed in an individual. Recognition of cancer-associated mutations by the immune system depends on the presence of a particular set of alleles, that elicit an immune response to fight against cancer. It indicates that the occurrence of specific HLA alleles also affects the outcome of the cancer patients. In the current study, prediction models have been developed using 415 skin cutaneous melanoma (SKCM) patients for predicting the overall survival of patients from their HLA-alleles. It has been observed that, the presence of certain superalleles in the patients, is responsible for improved overall survival which were referred as favourable superalleles like HLA-B*55 (HR=0.15, 95% CI 0.034 to 0.67), HLA-A*01 (HR=0.5, 95% CI 0.3 to 0.8). In contrast, presence of certain superalleles in the patients is responsible for their poor survival, those superalleles were referred as unfavourable superalleles such as HLA-B*50 (HR=2.76, 95% CI 1.284 to 5.941), HLA-DRB1*12 (HR=3.44, 95% CI 1.64 to 7.2). We developed prediction models using 14 HLA-superalleles and five clinical characteristics for predicting high-risk SKCM patients and achieve HR=4.52 (95% CI 3.088-6.609) with p-value = 8.01E-15. Lastly, we provide a web-based service to community for predicting the risk in SKCM patients (https://webs.iiitd.edu.in/raghava/skcmhrp/)